Athira Pharma to Present Updates from Phase 2/3 Trials of ATH-1017 at the 2021 Clinical Trials on Alzheimer’s Disease (CTAD) Conference

Rhea-AI Summary

Athira Pharma (NASDAQ: ATHA) announced updates on its ongoing Phase 2 and Phase 2/3 clinical trials for ATH-1017, a small molecule therapeutic targeting Alzheimer’s disease. The data will be presented at the 2021 Clinical Trials on Alzheimer’s Disease (CTAD) conference from Nov. 9-12, 2021. The presentation, titled "Phase 2/3 trials of ATH-1017," will be delivered by CMO Hans Moebius on Nov. 10 at 1:55 p.m. ET.

Positive

• Upcoming presentation of updates from Phase 2 and Phase 2/3 trials of ATH-1017 may enhance investor interest.
• ATH-1017 is designed to restore neuronal health, targeting Alzheimer’s disease, which addresses a significant market need.

Negative

• Presentation does not provide interim results or specific clinical outcomes, leading to uncertainty about ATH-1017's efficacy.
• -

BOTHELL, Wash., Sept. 29, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that updates and baseline data from two ongoing Phase 2 and Phase 2/3 clinical trials of its lead development candidate ATH-1017, a novel small molecule therapeutic specifically designed to enhance the activity of Hepatocyte Growth Factor (HGF) and its receptor MET, in mild-to-moderate Alzheimer’s disease, will be presented as an oral presentation at the upcoming 2021 Clinical Trials on Alzheimer’s Disease (CTAD) conference taking place Nov. 9-12, 2021 both virtually and in-person in Boston.

Oral Presentation Details:
Title: Phase 2/3 trials of ATH-1017, a novel treatment for mild-to-moderate Alzheimer's disease: Updates and baseline data
Presentation Number: OC10
Presenter: Hans Moebius, M.D., Ph.D., Chief Medical Officer, Athira Pharma
Date: Wednesday, Nov. 10, 2021
Time: 1:55 p.m. ET

About Athira Pharma, Inc.
Athira, headquartered in the Seattle area, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration. We aim to provide rapid cognitive improvement and alter the course of neurological diseases with our novel mechanism of action. Athira is currently advancing its lead therapeutic candidate, ATH-1017, a novel small molecule for Alzheimer’s and Parkinson’s dementia. For more information, visit www.athira.com. You can also follow Athira on Facebook, LinkedIn and @athirapharma on Twitter and Instagram.

Investor & Media Contact:
Julie Rathbun
Julie.rathbun@athira.com
206-769-9219

FAQ

What is the purpose of ATH-1017 clinical trials?

ATH-1017 is being tested for its effectiveness in treating mild-to-moderate Alzheimer’s disease.

When will the Phase 2/3 trial results for ATH-1017 be presented?

The results will be presented at the CTAD conference on November 10, 2021.

What are the implications of ATH-1017 for Alzheimer’s treatment?

If successful, ATH-1017 could offer a new therapeutic option for cognitive improvement in Alzheimer’s patients.

What is the significance of the CTAD conference for Athira Pharma?

The CTAD conference provides a platform to share critical trial updates, potentially influencing investor sentiment and market perception.